|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Pliant Therapeutics, Inc. (PLRX) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
68,801,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing therapies for the treatment of fibrosis and related diseases. Co.'s focus is on treating fibrosis by inhibiting integrin-mediated activation of TGF-ss. Co.'s main product candidate, PLN-74809, is a dual selective inhibitor of avss6 and avss1 integrins that Co. is developing for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. Co.'s second product candidate, PLN-1474, is a selective inhibitor of avss1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, which Co. has partnered with Novartis Institutes for Biomedical Research, Inc.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
79,496 |
79,496 |
140,276 |
753,616 |
Total Sell Value |
$918,974 |
$918,974 |
$1,966,214 |
$18,268,658 |
Total People Sold |
5 |
5 |
5 |
5 |
Total Sell Transactions |
5 |
5 |
10 |
45 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Hull Hans |
Chief Business Officer |
|
2023-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
54,000 |
192,191 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2023-01-25 |
4 |
AS |
$32.40 |
$487,517 |
D/D |
(15,000) |
93,812 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2023-01-25 |
4 |
OE |
$2.08 |
$31,200 |
D/D |
15,000 |
108,812 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2023-01-24 |
4 |
AS |
$30.89 |
$463,389 |
D/D |
(15,000) |
93,812 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2023-01-24 |
4 |
OE |
$2.08 |
$31,200 |
D/D |
15,000 |
108,812 |
|
- |
|
Cummings Keith Lamont |
Chief Financial Officer |
|
2023-01-23 |
4 |
AS |
$35.00 |
$1,050,000 |
D/D |
(30,000) |
84,424 |
|
- |
|
Cummings Keith Lamont |
Chief Financial Officer |
|
2023-01-23 |
4 |
OE |
$2.08 |
$134,850 |
D/D |
30,000 |
114,424 |
|
- |
|
Lefebvre Eric |
Chief Medical Officer |
|
2023-01-23 |
4 |
AS |
$34.48 |
$2,327,630 |
D/D |
(67,500) |
76,926 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2023-01-23 |
4 |
AS |
$35.00 |
$525,000 |
I/I |
(15,000) |
434,317 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2023-01-23 |
4 |
AS |
$33.71 |
$511,567 |
D/D |
(15,000) |
93,812 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2023-01-23 |
4 |
OE |
$2.08 |
$31,200 |
D/D |
15,000 |
108,812 |
|
- |
|
Ouimette Mike |
General Counsel & Corp. Secy |
|
2023-01-23 |
4 |
AS |
$34.19 |
$683,878 |
D/D |
(20,000) |
5,947 |
|
- |
|
Ouimette Mike |
General Counsel & Corp. Secy |
|
2023-01-23 |
4 |
OE |
$11.86 |
$361,800 |
D/D |
20,000 |
25,947 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2023-01-09 |
4 |
AS |
$19.17 |
$95,829 |
D/D |
(5,000) |
93,812 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2023-01-09 |
4 |
OE |
$2.08 |
$10,400 |
D/D |
5,000 |
98,812 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2023-01-06 |
4 |
AS |
$19.04 |
$285,584 |
D/D |
(15,000) |
93,812 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2023-01-06 |
4 |
OE |
$2.08 |
$31,200 |
D/D |
15,000 |
108,812 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2023-01-04 |
4 |
AS |
$19.06 |
$285,941 |
D/D |
(15,000) |
93,812 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2023-01-04 |
4 |
OE |
$2.08 |
$31,200 |
D/D |
15,000 |
108,812 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2023-01-03 |
4 |
AS |
$19.33 |
$289,952 |
D/D |
(15,000) |
93,812 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2023-01-03 |
4 |
OE |
$2.08 |
$31,200 |
D/D |
15,000 |
108,812 |
|
- |
|
Cummings Keith Lamont |
Chief Financial Officer |
|
2022-12-22 |
4 |
OE |
$2.08 |
$8,320 |
D/D |
4,000 |
84,424 |
|
- |
|
Cummings Keith Lamont |
Chief Financial Officer |
|
2022-12-20 |
4 |
S |
$19.10 |
$184,204 |
D/D |
(9,643) |
80,424 |
|
- |
|
Lefebvre Eric |
Chief Medical Officer |
|
2022-12-20 |
4 |
S |
$19.10 |
$207,968 |
D/D |
(10,887) |
144,426 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2022-12-20 |
4 |
S |
$19.10 |
$653,531 |
D/D |
(34,212) |
93,812 |
|
- |
|
133 Records found
|
|
Page 3 of 6 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|